Tirzepatide research began with an uneven pair

The molecule was built to stay

Tirzepatide is a synthetic 39-amino-acid peptide modeled on GIP, one of the gut hormones released after eating. A fatty-acid modification helps it bind albumin, a carrier protein in blood, so it remains in circulation much longer than the native hormones. Its half-life is approximately five days.

The 2018 discovery and proof-of-concept paper reported receptor assays in cells, experiments in mice, and an early human program with 142 subjects. In mice, it reduced body weight and food intake more than a selective GLP-1 receptor agonist. The early human work supported once-weekly administration and found lower fasting glucose and body weight than placebo. Those distinct stages demonstrate different aspects of the evidence.

The engineering is impressive to me. The more important surprise is that the pair is uneven: cell and primary-islet experiments in 2020 found stronger GIP-receptor engagement and a preference for certain GLP-1 signaling pathways over others. “Dual” describes this uneven engagement; the cell work alone leaves the explanation for a larger clinical result unproven.

Blood glucose results in SURPASS-2

In SURPASS-2, an open-label trial of 1,879 adults with type 2 diabetes over 40 weeks, weekly tirzepatide study arms of 5, 10 and 15 mg reduced HbA1c by 2.01, 2.24 and 2.30 percentage points. HbA1c reflects average blood glucose over roughly the preceding three months. Semaglutide 1 mg reduced it by 1.86 percentage points.

Weight reductions were also greater with tirzepatide, with treatment differences of -1.9, -3.6 and -5.5 kg. Gastrointestinal adverse events were the most common and were mostly mild or moderate. The chemistry and physiology review places these findings in the dual-incretin context: glucose-dependent insulin secretion, glucagon suppression, appetite reduction and delayed gastric emptying.

I’d resist translating better blood glucose into a claim about every long-term complication. The SURPASS-CVOT cardiovascular-outcomes comparison asked a different question, against dulaglutide, in adults with type 2 diabetes and established cardiovascular disease. Its existence matters precisely because the blood marker was not the whole answer.

The liver result includes its own restraint

The 2024 SYNERGY-NASH trial enrolled adults with metabolic dysfunction-associated steatohepatitis, or MASH, and moderate-to-severe fibrosis. MASH is a fatty-liver illness involving inflammation; fibrosis means scarring. Tirzepatide produced MASH resolution without worsening fibrosis more often than placebo.

“Without worsening” is doing real work in that result. A claim that every scar vanished or that the molecule treats all liver disease would exceed that result. I’d give that qualification the same prominence as the improvement. This finding also cannot expand the approval record by itself.

Breathing interruptions and a particular heart failure

The 2024 sleep-apnea trials studied adults with obesity and moderate-to-severe obstructive sleep apnea. Across 52 weeks, the apnea-hypopnea index, which counts breathing interruptions per hour, fell by 25.3 events/hour in the trial without positive-airway-pressure treatment and 29.3 events/hour in the trial with it, versus roughly 5 events/hour with placebo.

The 2025 SUMMIT report concerned heart failure with preserved ejection fraction and obesity. In that form of heart failure, the fraction of blood pumped out remains preserved despite the heart’s illness. Tirzepatide improved heart-failure outcomes and reduced events versus placebo in that population.

These studies broaden the clinical record considerably. To me, their strength is their specificity. Turning them into a general claim that tirzepatide fixes sleep or protects every heart would throw away the detail that makes them persuasive.

The people who stop count in the result

The 2026 review comparing tirzepatide with dulaglutide found similar overall adverse-event incidence, but discontinuation due to adverse events was 32% higher with tirzepatide, driven largely by gastrointestinal problems. The glycemic benefit was consistent at HbA1c below 7.0% in earlier-stage disease and smaller in longstanding disease with established cardiovascular disease.

Much of the highest-quality efficacy evidence comes from sponsor-funded trials. That does not undo randomization or the measured outcomes; it does make transparent comparisons and follow-up valuable. I’m less interested in a contest for the most impressive percentage than in whether the benefit remains usable over time.

The extended obesity and diabetes-prevention follow-up found sustained weight reduction and reduced progression to type 2 diabetes in adults with obesity and prediabetes. Withdrawal and body composition deserve the same prominence as that result.